

Claims:

1. A pharmaceutical composition which comprises a sodium channel blocker in combination with a selective serotonin uptake inhibitor.
2. A pharmaceutical composition according to claim 1, wherein the selective serotonin uptake inhibitor is selected from the group consisting of fluoxetine, paroxetine, duloxetine, sertraline, escitalopram and citalopram.
3. A pharmaceutical composition according to claim 1, wherein the sodium channel blocker is selected from the group consisting of lamotrigine, crobenetine, oxcarbamazepine and fosphenytoin.
4. A pharmaceutical composition according to any of claims 1, 2 or 3, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is lamotrigine.
5. A pharmaceutical composition according to any of claims 1, 2 or 3, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is crobenetine.
6. A pharmaceutical composition according to any of claims 1, 2 or 3, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is lamotrigine.
7. A pharmaceutical composition according to any of claims 1, 2 or 3, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is crobenetine.
8. The use of a sodium channel blocker and a selective serotonin uptake inhibitor in a process for the preparation of a pharmaceutical composition suitable for the treatment and/or the prevention of drug or alcohol addiction, incontinence of faeces and urine, inflammation, itching, intracranial edema, ischemia and/or subsequent damage caused by reperfusion or retinopathy, as a complication of glaucoma in mammals.
9. The use of a sodium channel blocker and a selective serotonin uptake inhibitor in a process for the preparation of a pharmaceutical composition suitable for the treatment and/or prevention of diseases in mammals, which involve chronic pain or epilepsy, or symptoms or diseases deriving from disorders and/or injuries of the motor system.

10. The use according to claim 8 or 9, wherein the selective serotonin uptake inhibitor is selected from the group consisting of fluoxetine, paroxetine, duloxetine, sertraline, escitalopram and citalopram.
11. The use according to claim 8 or 9, wherein the sodium channel blocker is selected from the group consisting of lamotrigine, crobenetine, oxcarbamazepine and phenytoin.
12. The use according to claim 8 or 9, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is lamotrigine.
13. The use according to claim 8 or 9, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is crobenetine.
14. The use according to claim 8 or 9, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is lamotrigine.
15. The use according to claim 8 or 9, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is crobenetine.
16. A method for the treatment and/or prevention of a disease occurring in a mammal, said disease involving chronic pain, epilepsy or deriving from disorders and/or injuries of the motor system, characterized in that a therapeutically effective amount of pharmaceutical composition comprising a sodium channel blocker and a selective serotonin uptake inhibitor is given to the subject in need of such treatment.
17. A method for the treatment and/or prevention of drug or alcohol addiction, incontinence of faeces and urine, inflammation, itching, intracranial edema, ischemia and/or subsequent damage caused by reperfusion or retinopathy, as a complication of glaucoma in mammals, characterized in that a therapeutically effective amount of pharmaceutical composition comprising a sodium channel blocker and selective serotonin uptake inhibitor is given to the subject in need of such treatment.
18. A method according to claim 16 or 17, wherein the selective serotonin uptake inhibitor is selected from the group consisting of fluoxetine, paroxetine, duloxetine, sertraline, escitalopram and citalopram.

19. A method according to claim 16 or 17, wherein the sodium channel blocker is selected from the group consisting of lamotrigine, crobenetine, oxcarbamazepine and phosphenytoin.
20. A method according to claim 16 or 17, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is lamotrigine.
21. A method according to claim 16 or 17, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is crobenetine.
22. A method according to claim 16 or 17, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is lamotrigine.
23. A method according to claim 16 or 17, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is crobenetine.